CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 10 No. 7 3
 

Patients and Physicians Differ on Chemotherapy Expectations

July 1, 2001

SAN FRANCISCO—Most cancer patients undergoing chemotherapy expect to be cured, even when cautioned by their physicians that the chemotherapy can only relieve symptoms, according to Geetha N. Varma, MD. Research conducted at three cancer clinics in the metropolitan Milwaukee area showed that patients and physicians agree on the goal of treatment less than half the time and that almost a quarter of patients do not have a realistic idea of the likelihood of achieving the goal.

"This appears to be a problem with how informed consent is used," Dr. Varma told Oncology News International. "Even when the doctor said palliation, half of the time the patient thought that chemotherapy should produce a cure."

Dr. Varma and colleagues surveyed cancer patients undergoing chemotherapy and their treating physicians. Dr. Varma was affiliated with Sinai Samaritan Hospital in Milwaukee at the time of the report, but beginning in July will be a fellow in medical oncology/hematology at Roswell Park Cancer Institute in Buffalo, New York.

Identifying Goals

Patients and physicians were asked to identify the goal of chemotherapy (cure or palliation) and the likelihood of achieving that goal. Subjects were also asked about life expectancy, chemotherapy toxicity, and the burdens and benefits of chemotherapy. Patient questionnaires were completed by direct interview, and compared to similar, self-administered, questionnaires completed by their oncologists.

Data were available from 74 of 75 patients and from 66 of 75 physicians. Patients had breast cancer (33%), lung cancer (15%), colon cancer (14%), lymphomas (9%), or other forms of cancer (29%).

"Overall agreement on the goal of treatment was poor," Dr. Varma reported. "When doctors identified the goal as palliation, 67% of patients thought that the goal of treatment was cure. However, in those cases where the doctors identified the goal as cure (20%), agreement with their patients was high (93%). When the doctor and patient agreed on the goal (45%), patients had higher expectations for success than their doctors—80% vs 60%," Dr. Varma continued.

Twenty-three percent of patients did not know the likelihood of achieving the identified goal of the chemotherapy. Sixty percent of patients did not know how long they might live without chemotherapy, or how much longer they might live with chemotherapy. Ninety-five percent of patients understood that chemotherapy had toxicity.

Communication Breakdown

"Also, the majority of patients were unaware of alternatives to the recommended chemotherapy treatment," Dr. Varma said.

Patients and physicians share an unrealistic notion of how well they are communicating. Ninety-eight percent of patients and 94% of doctors were satisfied with the patients’ understanding of the burdens and benefits of chemotherapy.

"Even though doctors and patients think that patients have a good understanding about chemotherapy, the vast majority of patients fail to understand two of the three essential components of adequate informed consent," Dr. Varma said. "They understand the risk of chemotherapy, but they do not understand the benefits or alternatives to the proposed treatment. We must therefore question the adequacy of our current informed consent process."

The answer might appear to be more written information for the patient and more time for discussion between patient and physician. In the current healthcare environment, however, "spending more time may not be a realistic option for these doctors," Dr. Varma observed.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
  • ASCO: PD-L1 Antibody Elicits Durable Response in RCC
  • RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy